Research and Markets: Epigenetic Targets in Drug Discovery - Everything a Drug Researcher Needs to Know about Targeting Epigenetic Mechanisms of Disease
* Reuters is not responsible for the content in this press release.
DUBLIN--(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/475fd2/epigenetic_targets) has announced the addition of John Wiley and Sons Ltd's new report "Epigenetic Targets in Drug Discovery" to their offering. Fueled by the expertise of a team of international specialist authors, this first reference on the booming topic covers everything a drug researcher needs to know about targeting epigenetic mechanisms of disease. The first part of the book surveys current methodologies for finding and validating drug candidates that act via epigenetic mechanisms. The second part systematically surveys known and suspected drug targets within the epigenetic machinery, including the discovery and development of vorinostat, the first marketed epigenetic drug. Key Topics Covered: PART I: General aspects and methodologies. 1 New Frontiers in Epigenetic Modifications. 2 Structural Biology of Epigenetic Targets. 3 Computer- and Structure-based Lead Identification for Epigenetic Targets. 4 Histone Modification Analysis Using Mass Spectrometry. 5 In-vitro Assays for Histone Modifying Enzymes. 6 Epigenetic Targets in Drug Discovery: Cell-based assays for HDAC inhibitor hit validation. 7 Chromatin Immuno Precipitation ChIP: wet lab meets in silico. PART II: Epigenetic Target Classes and Inhibitor Development. 8 DNA Methyltransferase Inhibitors. 9 Histone Deacetylase Inhibitors. 10 NAD-Dependent Deacetylases as Therapeutic Targets. 11 Inhibitors of Histone Acetyltransferases: Discovery and Biomedical Perspectives. 12 Histone Methyltransferases as Novel Drug Targets. 13 Histone Demethylases. For more information visit http://www.researchandmarkets.com/research/475fd2/epigenetic_targets Laura Wood Senior Manager press@researchandmarkets.com Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Copyright Business Wire 2009
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.



Follow Reuters